This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

Novel Pharmacologic Targets for the Treatment of Negative Symptoms in Schizophrenia

Robert W. Buchanan, MD

Published: May 15, 2013

Article Abstract

While positive symptoms of schizophrenia tend to respond well to antipsychotic therapy, negative symptoms remain refractory in many patients. Evidence for N-methyl-d-aspartate (NMDA) glutamate receptor hypofunction in patients with schizophrenia has led to establishing novel treatment targets for resolving those symptoms. This activity reviews glutamatergic agents in the treatment of negative and cognitive symptoms, including the NMDA receptor agonists and partial agonists glycine, d-serine, and d-cycloserine; the glycine transporter inhibitors sarcosine and RG1678; and ampakines, positive allosteric modulators of AMPA glutamate receptors.

See the entire activity.


Related Articles

Volume: 74

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...